Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how non-Hodgkin's lymphoma that has not responded
to, or that has returned after standard treatment, responds to bortezomib, rituximab and
bendamustine, and also to see what effects this drug combination have on this cancer.